Afatinib versus methotrexate as second-line treatment in Asian patients with recurrent or metastatic squamous cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 3): an open-label, randomised phase III trial
Titel:
Afatinib versus methotrexate as second-line treatment in Asian patients with recurrent or metastatic squamous cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 3): an open-label, randomised phase III trial
Auteur:
Guo, Y. Ahn, M.-J. Chan, A. Wang, C.-H. Kang, J.-H. Kim, S.-B. Bello, M. Arora, R.S. Zhang, Q. He, X. Li, P. Dechaphunkul, A. Kumar, V. Kamble, K. Li, W. Kandil, A. Cohen, E.E.W. Geng, Y. Zografos, E. Tang, P.Z.